| News
Switzerland excels with biotech start-ups
06.05.2019
According to an article in the journal “Nature”, Switzerland is the European leader with its biotech start-up ecosystem. Based on population size, Switzerland ranks in first place for both venture capital and patent and research output.

Biotech (img: angellodeco/shutterstock)
An article in the journal “Nature” examines the European biotech start-up ecosystem and compares the ecosystems in the individual countries. For example, it measures the number of biotech start-ups that were able to raise venture capital between 2013 and 2017. In absolute numbers, the UK leads followed by France and Switzerland. However, Switzerland ranks the highest based on population size, followed by Denmark and Ireland in second place.
In addition to venture capital raised, the article also looks at research productivity. Per capita Switzerland is also the leader in this field across Europe, followed by Denmark, Sweden and the Netherlands. According to the article, this can be explained by the high level of R&D spending. At 3.4%, Switzerland is also the European country with the highest R&D spending as a percentage of gross domestic product (GDP).
On a per capital basis, Switzerland also ranks highest across Europe in terms of biotech patents. It also performs well in the area of human capital and is in third place behind Denmark and the Netherlands based on the number of clinical trials per capita.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read MoreBSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read MoreUptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read MoreSouth Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read More